Hims & Hers Scraps Compounded GLP-1 Pill Program
Hims & Hers has abruptly shelved its GLP‑1 weight-loss pill offering and now faces a patent battle with Novo Nordisk, marking a dramatic escalation in the fight over compounded weight‑loss medications. Telehealth provider Hims & Hers confirmed it has stopped offering the compounded semaglutide tablet version of Novo Nordisk’s Wegovy just days after publicizing the product — a major reversal triggered by legal pressure and regulatory scrutiny. The company first launched the low‑cost alternative but pulled it amid threats from Novo Nordisk and warnings from FDA commissioner Marty Makary.
Novo Nordisk on Monday (2/9) filed a patent infringement lawsuit against Hims & Hers, arguing that the telehealth company’s compounded semaglutide products violate its intellectual property protecting semaglutide‑based treatments, including Wegovy and Ozempic. The Danish drugmaker is seeking a permanent injunction barring Hims from selling infringing products and monetary damages, according to the complaint.
FDA’s involvement was a critical turning point. On 2/6, the agency signaled it would crack down (see story) on compounded GLP‑1 products that it cannot verify for quality, safety, or efficacy, a stance that directly challenged the legality of Hims’ pill offering. That regulatory stance, paired with Novo’s lawsuit, effectively undercut Hims’ ability to pursue its low‑price strategy in the GLP‑1 space.
The Hims & Hers episode is the latest chapter in a multi-year regulatory arc around GLP‑1 compounding, according to a law perspective post by Buchanan Ingersoll & Rooney. The company’s 2024 experiment with compounded oral semaglutide marked the beginning of a broader reckoning that moved from regulatory ambiguity and manufacturer pressure to coordinated federal enforcement by 2025 and early 2026.
By 2024, GLP-1 receptor agonists like semaglutide and tirzepatide had transformed obesity and diabetes care, producing clinically meaningful weight loss, the law firm says. Demand far outstripped supply, creating prolonged shortages and injection aversion at prices exceeding $1,000 per month. The FDA’s shortage designations allowed compounding pharmacies, under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, to prepare limited versions for patients with medical necessity. Yet compounding was never intended as a consumer-scale manufacturing substitute — it existed as a narrow exception.
Against this backdrop, Hims & Hers initially offered compounded injectable semaglutide in 2024. Its oral semaglutide pill, however, did not exist in FDA-approved oral form at obesity-level dosing, and oral peptide delivery presents well-known scientific challenges, the perspective piece says, noting that Novo Nordisk had spent years developing proprietary technology and clinical data to bring oral semaglutide to market for diabetes. While no FDA guidance explicitly prohibited oral compounded GLP-1s at the time, the risk was clear: unapproved dosage forms, consumer-facing marketing, and direct competition with a branded manufacturer pushed the product to the edge of regulatory tolerance, the law firm says.
Throughout 2024, Novo Nordisk applied sustained pressure on Hims and other market participants, raising safety and bioavailability concerns. The company also signaled readiness to escalate beyond civil remedies, including potential Department of Justice involvement, creating asymmetric legal risk for telehealth platforms, according to the law firm.
By 2025, FDA drew clear regulatory lines. Shortages were formally declared resolved, removing the statutory basis for routine compounding. Compounded products outside narrow, documented patient-specific medical necessity were presumptively unlawful, and Warning Letters targeted compounding pharmacies, telehealth platforms, and marketing claims suggesting equivalence to approved drugs.
And this year so far has provided further clarification: patient-specific compounding by licensed pharmacies remained lawful, but FDA emphasized enforcement priorities, including unlicensed manufacturing, misleading marketing, improper storage, and research-grade ingredient use. The narrow pathway left for compounded GLP-1s effectively closed, the perspective piece contends.
Viewed in this context, Hims’ withdrawal was inevitable, according to the law firm. Scientific uncertainty, regulatory exposure, and manufacturer opposition combined to make the oral formulation unsustainable. The episode serves as an early signal of the shrinking tolerance for broad GLP-1 compounding. The law firm says that for pharmacies and telehealth platforms, the message is clear: patient-specific documentation, conservative marketing, validated supply chains, and compliance systems are now mandatory. What began as regulatory gray space has become a tightly policed corridor, and ignoring this shift is no longer bold innovation — it is regulatory exposure, it says.